(MedPage Today) — CHICAGO — Adding an investigational TROP2-targeted antibody-drug conjugate (ADC) to first-line immunotherapy for PD-L1-positive non-small cell lung cancer (NSCLC) reduced the risk of disease progression and may have improved…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
